TY - JOUR
T1 - Recalibrating intellectual property rights to enhance translational research collaborations
AU - Bubela, Tania
AU - FitzGerald, Garret A.
AU - Gold, E. Richard
PY - 2012/2/22
Y1 - 2012/2/22
N2 - Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.
AB - Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.
UR - http://www.scopus.com/inward/record.url?scp=84857493444&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3003490
DO - 10.1126/scitranslmed.3003490
M3 - Comment/debate
C2 - 22357536
AN - SCOPUS:84857493444
SN - 1946-6234
VL - 4
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 122
M1 - 122cm3
ER -